Margarita Guerrero‐Jiménez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margarita Guerrero‐Jiménez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Luis Gutiérrez-Rojas
Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain
4 shared publications Carmen Maura Carrillo de Albornoz Calahorro
Department of Psychiatry Hospital Universitario Virgen de las Nieves Granada Andalucía Spain
2 shared publicationsAlejandro Porras Segovia
Department of Psychiatry Hospital Universitario Fundación Jiménez Díaz Madrid Madrid Spain
1 shared publication- Alex Spiers
Royal Devon and Exeter NHS Foundation Trust Hospital, Exeter, UK
1 shared publication Blanca Gutiérrez
Department of Psychiatry, Faculty of Medicine, University of Granada, Granada, Spain
1 shared publication- Braulio Girela-Serrano
Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, United Kingdom
1 shared publication
Latest Publications
- 20 April 2021
- Published by SAGE Publications in International Journal of Social Psychiatry
- Vol. 68 (4) , 898-907
Psychotic symptoms associate inversely with social support, social autonomy and psychosocial functioning: A community-based study
Population-based studies exploring psychotic symptoms (PS) show that their prevalence in the community is higher than previously thought. Psychosocial functioning and social support are poorer among people presenting clinical and subclinical PS. We aimed to estimate the prevalence rate of PS in Andalusia and to explore the association between PS and psychosocial functioning, social support and social autonomy in a Southern European population. This is a cross-sectional study. We undertook multi-stage sampling using different standard stratification techniques. Out of 5496 households approached, we interviewed 4507 (83.7%) randomly selected participants living in the autonomous region of Andalusia (Southern Spain). The Spanish version of the MINI International Neuropsychiatric Interview was used to elicit PS. We also gathered information on socio-demographic factors, suicidality risk, psychosocial functioning, social support and social autonomy. The overall prevalence of PS was 6.7% (95% CI: 5.99–6.45). PS were associated with lower age (OR 0.975; 95% CI (0.967–0.983); p < .0001), female gender (OR = 1.346; 95% CI (1.05–1.07) p = .018), not living in a rural area (OR = 0.677; 95% CI (0.50–0.90) p = 0.009), lower social support (OR = 0.898; 95% CI (0.85–0.94) p < .0001), lower scores on social autonomy (OR = 0.889; 95% CI (0.79–1.00) p = .050), having an increased suicidality risk score (OR = 1.038; 95% CI (1.005–1.07); p = .023) and having lower scores on psychosocial functioning (OR = 0.956; 95% CI (0.95–0.96); p < 0.0001). Social outcomes seem to be strongly inversely associated with PS in spite of presumed higher levels of social support among Southern European cultures.
- 20 April 2021
- Published by SAGE Publications in International Journal of Social Psychiatry
- Vol. 68 (4) , 898-907
Psychotic symptoms associate inversely with social support, social autonomy and psychosocial functioning: A community-based study
Population-based studies exploring psychotic symptoms (PS) show that their prevalence in the community is higher than previously thought. Psychosocial functioning and social support are poorer among people presenting clinical and subclinical PS. We aimed to estimate the prevalence rate of PS in Andalusia and to explore the association between PS and psychosocial functioning, social support and social autonomy in a Southern European population. This is a cross-sectional study. We undertook multi-stage sampling using different standard stratification techniques. Out of 5496 households approached, we interviewed 4507 (83.7%) randomly selected participants living in the autonomous region of Andalusia (Southern Spain). The Spanish version of the MINI International Neuropsychiatric Interview was used to elicit PS. We also gathered information on socio-demographic factors, suicidality risk, psychosocial functioning, social support and social autonomy. The overall prevalence of PS was 6.7% (95% CI: 5.99–6.45). PS were associated with lower age (OR 0.975; 95% CI (0.967–0.983); p < .0001), female gender (OR = 1.346; 95% CI (1.05–1.07) p = .018), not living in a rural area (OR = 0.677; 95% CI (0.50–0.90) p = 0.009), lower social support (OR = 0.898; 95% CI (0.85–0.94) p < .0001), lower scores on social autonomy (OR = 0.889; 95% CI (0.79–1.00) p = .050), having an increased suicidality risk score (OR = 1.038; 95% CI (1.005–1.07); p = .023) and having lower scores on psychosocial functioning (OR = 0.956; 95% CI (0.95–0.96); p < 0.0001). Social outcomes seem to be strongly inversely associated with PS in spite of presumed higher levels of social support among Southern European cultures.
- Open Access
- 14 April 2021
- Published by Wiley in General Psychiatry
- Vol. 34 (2) , e100254
Psychosis and Dandy‐Walker syndrome: a case report and review of the literature
Dandy‐Walker syndrome (DWS) is a group of brain malformations which sometimes present with psychotic symptoms. We present the case of a patient diagnosed with Dandy‐Walker variant who presented with schizophrenia‐like psychosis. A man in his 30s was admitted to an acute psychiatric unit presenting with persecutory delusions, auditory hallucinations and violent behaviour. The MRI performed showed the typical alterations of Dandy‐Walker variant: vermian hypoplasia and cystic dilatation of the fourth ventricle. He also suffered from mild intellectual disability. After being treated with olanzapine 10 mg/d for a month, his psychotic symptoms greatly improved and he was discharged. In conclusion, DWS may cause psychosis through a dysfunction in the circuit connecting prefrontal, thalamic and cerebellar areas. The association between these two conditions may contribute to the understanding of the aetiopathogenesis of schizophrenia.
- 14 April 2021
- Published by Wiley in General Psychiatry
- Vol. 34 (2) , e100254
Open AccessPsychosis and Dandy‐Walker syndrome: a case report and review of the literature
Dandy‐Walker syndrome (DWS) is a group of brain malformations which sometimes present with psychotic symptoms. We present the case of a patient diagnosed with Dandy‐Walker variant who presented with schizophrenia‐like psychosis. A man in his 30s was admitted to an acute psychiatric unit presenting with persecutory delusions, auditory hallucinations and violent behaviour. The MRI performed showed the typical alterations of Dandy‐Walker variant: vermian hypoplasia and cystic dilatation of the fourth ventricle. He also suffered from mild intellectual disability. After being treated with olanzapine 10 mg/d for a month, his psychotic symptoms greatly improved and he was discharged. In conclusion, DWS may cause psychosis through a dysfunction in the circuit connecting prefrontal, thalamic and cerebellar areas. The association between these two conditions may contribute to the understanding of the aetiopathogenesis of schizophrenia.
- 18 March 2021
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 16 (2) , 113-125
Obesity and overweight among children and adolescents with bipolar disorder from the general population: A review of the scientific literature and a meta‐analysis
There is substantial evidence of the high prevalence of obesity (OB) and overweight (OW) and their association with increased medical and psychiatric burden among adults with bipolar disorder (BD). However, little is known regarding its prevalence among young people with BD, other than the risk from psychotropic medication, which has been the focus of research in this population. We present a systematic review and meta‐analysis of the literature on prevalence and correlates of OB and OW children and adolescents with BD using a different perspective than impact of medication. Four studies met inclusion criteria. The prevalence of OB in children and adolescents with BD was 15% (95% CI 11–20%). We observed a higher prevalence of OB in comparison to the general population. Different studies found significant associations between OB, OW, and BD in young populations including non‐Caucasian race, physical abuse, suicide attempts, self‐injurious behaviours, psychotropic medication, and psychiatric hospitalizations.
- 18 March 2021
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 16 (2) , 113-125
Obesity and overweight among children and adolescents with bipolar disorder from the general population: A review of the scientific literature and a meta‐analysis
There is substantial evidence of the high prevalence of obesity (OB) and overweight (OW) and their association with increased medical and psychiatric burden among adults with bipolar disorder (BD). However, little is known regarding its prevalence among young people with BD, other than the risk from psychotropic medication, which has been the focus of research in this population. We present a systematic review and meta‐analysis of the literature on prevalence and correlates of OB and OW children and adolescents with BD using a different perspective than impact of medication. Four studies met inclusion criteria. The prevalence of OB in children and adolescents with BD was 15% (95% CI 11–20%). We observed a higher prevalence of OB in comparison to the general population. Different studies found significant associations between OB, OW, and BD in young populations including non‐Caucasian race, physical abuse, suicide attempts, self‐injurious behaviours, psychotropic medication, and psychiatric hospitalizations.
- Open Access
- 5 August 2019
- Published by Wiley in General Psychiatry
- Vol. 32 (4) , e100075
Successful treatment of psychosis induced by interferon alpha and ribavirin with paliperidone: first case reported
Several clinical studies have shown a large number of mental symptoms by immunomodulatory treatment with interferon (IFN). The most frequently described symptoms are depression, suicidal behaviour, manic symptoms, anxiety, psychosis and delirium, associated with other non‐specific symptoms such as fatigue, irritability, psychomotor retardation, decreased libido, insomnia, difficulty in concentration and attention. Having a history of mental disorder contraindicates the use of IFN‐alpha. These adverse effects that affect the mental state appear usually at the beginning of the treatment (most after 3 weeks of treatment). The incidence of psychotic episodes is low and the episodes usually remit when treatment is interrupted; only some cases require antipsychotic treatment. We present the case of a patient affected with hepatitis C who began to present self‐referential delirious symptoms after receiving the treatment with IFN and who was successfully treated with paliperidone. This patient could be classified within the group of high‐risk psychiatric patients given the family history of schizophrenia and his personal history of illegal drug consumption. The pharmacological actions of paliperidone are similar to other high potency atypical antipsychotics. The receptor‐binding profile of paliperidone most closely resembles that of risperidone and ziprasidone. Paliperidone differs from risperidone and most other antipsychotics by its relatively low extent of enzymatic hepatic metabolism. To the best of our knowledge, this is the first case described that was successfully treated with paliperidone.
- 5 August 2019
- Published by Wiley in General Psychiatry
- Vol. 32 (4) , e100075
Open AccessSuccessful treatment of psychosis induced by interferon alpha and ribavirin with paliperidone: first case reported
Several clinical studies have shown a large number of mental symptoms by immunomodulatory treatment with interferon (IFN). The most frequently described symptoms are depression, suicidal behaviour, manic symptoms, anxiety, psychosis and delirium, associated with other non‐specific symptoms such as fatigue, irritability, psychomotor retardation, decreased libido, insomnia, difficulty in concentration and attention. Having a history of mental disorder contraindicates the use of IFN‐alpha. These adverse effects that affect the mental state appear usually at the beginning of the treatment (most after 3 weeks of treatment). The incidence of psychotic episodes is low and the episodes usually remit when treatment is interrupted; only some cases require antipsychotic treatment. We present the case of a patient affected with hepatitis C who began to present self‐referential delirious symptoms after receiving the treatment with IFN and who was successfully treated with paliperidone. This patient could be classified within the group of high‐risk psychiatric patients given the family history of schizophrenia and his personal history of illegal drug consumption. The pharmacological actions of paliperidone are similar to other high potency atypical antipsychotics. The receptor‐binding profile of paliperidone most closely resembles that of risperidone and ziprasidone. Paliperidone differs from risperidone and most other antipsychotics by its relatively low extent of enzymatic hepatic metabolism. To the best of our knowledge, this is the first case described that was successfully treated with paliperidone.
- Open Access
- 16 July 2019
- Published by Wiley in General Psychiatry
- Vol. 32 (3) , e100066
Wilson disease and psychiatric symptoms: A brief case report
Wilson disease (WD) is an uncommon recessive genetic disorder affecting copper metabolism. Cardiac, neurological, hepatic and renal manifestations are well defined, nevertheless approximately 30% of patients debut with neuropsychiatric symptoms. These psychiatric alterations resulting from the accumulation of this heavy metal in the basal ganglia are some how less specific. We present a short review of psychiatric symptoms of WD and describe a case of a 37‐year‐old woman diagnosed with WD who presented neuropsychiatric symptoms and had a consequent delay in diagnosis and causal treatment. Patients who develop WD starting with a predominance of neuropsychiatric symptoms tend to manifest hepatic symptoms later, therefore have a longer delay of diagnosis and a poorer outcome than patients with hepatic symptoms. An early diagnosis of WD can avoid irreversible neurological damage.
- 16 July 2019
- Published by Wiley in General Psychiatry
- Vol. 32 (3) , e100066
Open AccessWilson disease and psychiatric symptoms: A brief case report
Wilson disease (WD) is an uncommon recessive genetic disorder affecting copper metabolism. Cardiac, neurological, hepatic and renal manifestations are well defined, nevertheless approximately 30% of patients debut with neuropsychiatric symptoms. These psychiatric alterations resulting from the accumulation of this heavy metal in the basal ganglia are some how less specific. We present a short review of psychiatric symptoms of WD and describe a case of a 37‐year‐old woman diagnosed with WD who presented neuropsychiatric symptoms and had a consequent delay in diagnosis and causal treatment. Patients who develop WD starting with a predominance of neuropsychiatric symptoms tend to manifest hepatic symptoms later, therefore have a longer delay of diagnosis and a poorer outcome than patients with hepatic symptoms. An early diagnosis of WD can avoid irreversible neurological damage.